Abstract
Promising outcomes from recent preclinical studies and/or early clinical trials with melanocortin receptor antagonists and ghrelin mimetics raise hopes that safe and effective anti-cachexia drugs will soon become available for widespread clinical use.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 266-271 |
| Number of pages | 6 |
| Journal | Current opinion in supportive and palliative care |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 2010 |
Keywords
- Cachexia
- Cytokines
- Ghrelin
- Inflammation
- Melanocortin
ASJC Scopus subject areas
- Oncology
- Oncology(nursing)
- Critical Care and Intensive Care Medicine